Difference between revisions of "Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5 (Q9821)"

From Wikibase.slis.ua.edu
Jump to navigation Jump to search
(‎Created claim: Published In Name String (P102): Blood, #quickstatements; #temporary_batch_1590006349955)
(‎Created claim: Page(s) (P105): 342-342, #quickstatements; #temporary_batch_1590074839150)
 
(2 intermediate revisions by the same user not shown)
Property / Volume
 +
128
Property / Volume: 128 / rank
 +
Normal rank
Property / title
 +
Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (English)
Property / title: Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (English) / rank
 +
Normal rank
Property / Page(s)
 +
342-342
Property / Page(s): 342-342 / rank
 +
Normal rank

Latest revision as of 15:45, 21 May 2020

Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Pemmaraju N, et al. Blood (2016) cited as Ref 558 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Pemmaraju N
    0 references
    2016
    0 references
    Blood
    0 references
    128
    0 references
    Results from phase 2 trial ongoing expansion stage of SL-401 in patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) (English)
    0 references
    342-342
    0 references